Back to top

Lobbying Update: $60,000 of BRISTOL-MYERS SQUIBB lobbying was just disclosed

$60,000 of BRISTOL-MYERS SQUIBB lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy."

You can find more data on corporate lobbying on Quiver Quantitative.

BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

BMY Insider Trading Activity

BMY Insider Trades

BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

  • DAVID V ELKINS (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,850,016.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

BMY Hedge Fund Activity

We have seen 1,138 institutional investors add shares of BMY stock to their portfolio, and 990 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

BMY Analyst Ratings

Wall Street analysts have issued reports on $BMY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Piper Sandler issued a "Overweight" rating on 02/23/2026

To track analyst ratings and price targets for BMY, check out Quiver Quantitative's $BMY forecast page.

BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 10 analysts offer price targets for $BMY in the last 6 months, with a median target of $62.0.

Here are some recent targets:

  • Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 07/06/2026
  • Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026
  • Seamus Fernandez from Guggenheim set a target price of $72.0 on 04/08/2026
  • Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
  • Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
  • David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026
  • Emily Field from Barclays set a target price of $75.0 on 02/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bristol Myers Squibb Company (BMY)